Rosy  Wills

Rosy Wills

Followers 0
Following 0
According to research report the global oral care market is projected to reach USD 53.97 billion by 2022 from USD 43.31 billion in 2017, at a CAGR of 4.5%.Factors such as the growing awareness regarding oral hygiene, rising incidence of dental caries and other periodontal diseases, and technological advancements in oral care products are the key drivers of this market.Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80546246In this report, the market is segmented on the basis of product, distribution channel, and region.On the basis of product, the global oral care market is segmented into toothpaste, toothbrushes and accessories, mouthwashes/rinses, denture products, dental accessories/ancillaries, and dental prosthesis cleaning solutions.The toothbrushes and accessories segment is expected to register the highest CAGR during the forecast period.Growing innovation in toothbrushes and rising adoption of technologically advanced toothbrushes are fuelling the growth of this segment.Based on distribution channel, the market is segmented into consumer stores, retail pharmacies, online distribution, and dental dispensaries.The online distribution segment is expected to grow at the highest rate during the forecast period.
According to research report the global hyperspectral imaging systems market is projected to reach USD 21.33 billion by 2023 from USD 9.51 billion in 2018, at a CAGR of 17.5%.The growing industrial applications of hyperspectral imaging and increasing funding & investments are the major factors driving the growth of the global hyperspectral imaging systems market.However, data storage issues and high costs associated with the use of hyperspectral imaging are expected to restrain the growth of this market during the forecast period.The hyperspectral imaging systems market is categorized into two product segments, namely, cameras and accessories.The cameras segment is expected to command the largest share of the global hyperspectral imaging systems market in 2018.Factors such as recent advances in sensor development and computing power and the availability of low-cost cameras with widening industrial applications are driving the growth of this market segment.Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=246979343On the basis of application, the hyperspectral imaging systems market is segmented into military surveillance, remote sensing, machine vision & optical sorting, life sciences & medical diagnostics, and other applications.The life sciences and medical diagnostics segment is expected to grow at the highest CAGR during the forecast period.The high growth of this segment is attributed to various advantages associated with hyperspectral imaging, such as early detection of various types of cancer and retinal diseases.On the basis of remote sensing application, the hyperspectral imaging systems market is segmented into agriculture, environmental monitoring, mining/mineral mapping, and other remote sensing applications.
According to research report the global contrast media market is expected to reach USD 5.53 billion by 2022 from an estimated USD 4.57 billion in 2017, growing at a CAGR of 3.9% during the forecast period.The increasing number of research and funding activities for research of contrast agents and their applications provides immense opportunities for players in the contrast media market.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=911Market developments (regulatory and product approvals); agreements, collaborations, contracts, and partnerships; expansions; mergers and acquisitions; and other strategies (divestments, grants, and website launches) were some of the strategies adopted by players from 2014 and 2017.The key players that adopted these strategies include GE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare (Germany), and Guerbet (France).GE Healthcare held the first position in the global contrast media market in 2017.Some subsidiaries of the firm include GE Healthcare USA Holdings, Inc., GE Healthcare Ltd. (Japan), GE Healthcare Biosciences AB (US), and GE Healthcare AS (Norway).GE Healthcare received the Norwegian Medicines Agency's (NOMA) approval for SONAZOID, a contrast agent used in ultrasound imaging of focal liver lesions.The company’s robust product portfolio, large number of subsidiaries, focus on customers, and new product launches have also helped expand its share in the market.Bracco Imaging was the second largest player in the contrast media market in 2017.
According to research the research report Life Science Analytics Market is projected to reach USD 33.2 billion by 2024 from USD 19.3 billion in 2019, at a CAGR of 11.5% during the forecast period.Growth in this market is mainly driven by technological advancements, big data in the life science industry, growing adoption of analytics solutions in clinical trials, increasing adoption of analytics for sales and marketing applications, need for improved data standardization, increasing prevalence of chronic diseases, growing pressure to curb healthcare spending, and the need for improved patient outcomes.On the other hand, high implementation costs are expected to restrain the growth of this market to a certain extent.Read More - https://www.marketsandmarkets.com/PressReleases/life-science-analytics.asp “The on-demand model segment is expected to grow at the highest CAGR during the forecast period.”Based on delivery model, the life science analytics market is segmented into the on-demand model and on premise model.The on-demand model segment is expected to grow at the highest CAGR during the forecast period, owing to advantages such as growing demand for self-driven analytics, lack of upfront capital investments for hardware, extreme capacity flexibility, and pay-as-you-go pricing of this model.“The descriptive analytics segment accounted for the largest market share in 2018.”Based on type, the life science analytics market is segmented into descriptive analytics, predictive analytics, and prescriptive analytics.The descriptive analytics segment accounted for the largest share of the life science analytics market in 2018.The large share of this segment is attributed to the significant usage of descriptive analytics by stakeholders to gain a better understanding of the past trends and events occurring in real-time.
According to research report the clinical microbiology market is expected to reach USD 4.95 billion by 2023 from USD 3.63 billion in 2018 growing at a CAGR of 6.4% during forecast period.Growth in clinical microbiology market can be attributed to factors such as rising incidence of infectious diseases and growing outbreak of epidemics and increased funding and public-private investments.Read More: https://www.marketsandmarkets.com/PressReleases/microbiology-testing.aspMarket Size EstimationA detailed market estimation approach was followed to estimate and validate the size of the clinical microbiology market and other dependent submarkets, as mentioned above.The key players in the clinical microbiology market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research.Research methodology includes the study of the annual and quarterly financial reports of the top market players as well as interviews with industry experts for key insights (both quantitative and qualitative trends) on the clinical microbiology market.All percentage shares, splits, and breakdowns were determined by using secondary sources and verified through primary sources.All the possible parameters that affect the market segments covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.This data was consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report.
According to the new market research report dPCR and qPCR Market is projected to reach USD 6.3 billion by 2024 from USD 4.1 billion in 2019, at a CAGR of 8.8%.The rising incidences of target diseases (such as HIV, malaria, tuberculosis, and cancer) and genetic disorders; increasing use of biomarker profiling for disease diagnosis and monitoring; and successful completion of the Human Genome Sequencing Project are a few key factors driving the growth of this market.In addition, ongoing technological advancements in PCR technologies and support for genomic research have contributed to market growth.Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalyst.asp?id=174151204  Reagents and consumables to dominate the qPCR market in 2019Reagents and consumables are expected to account for the largest share among qPCR product categories in 2019.The large share of this segment is due to the expanding applications of qPCR (owing to its technological benefits over traditional PCR), growing private-public funding for life science research, and the rising number of probe-based multiplex genetic analysis procedures (that require the analysis of low-volume gene samples).Instruments to be the fastest-growing segment among dPCR products during the forecast periodThe dPCR instruments segment is expected to grow at the fastest CAGR among dPCR products during the forecast period.The high growth of this segment will be driven by the procedural benefits offered by dPCR over qPCR (such as reduced throughput time, elimination of reference standards, absolute sample quantification, and high accuracy), growing demand for dPCR (particularly in forensics and drug discovery), and the rising number of dPCR-based genetic research activities across the globe.Geographically, Asia Pacific is expected to be the fastest-growing market segmentNorth America accounts for the largest share of the dPCR and qPCR market.
A number of key players are competing against each other to expand their existing customer base.Getinge Group (Sweden), Medtronic plc (Ireland), and LivaNova PLC (U.K.) are the top three players of the extracorporeal membrane oxygenation (ECMO) machine market.These players jointly accounted for a share of 65% to 70% of the total ECMO machine market in 2015.Know more: https://www.marketsandmarkets.com/PressReleases/extracorporeal-membrane-oxygenation-systems.aspGetinge Group is the largest player in the global market.The company offers its ECMO products under its Maquet brand.The company also develops innovative products such as CARDIOHELP system which is a portable heart-lung support system in the market.Moreover, in September 2015, the company partnered with iMDsoft GmbH (Germany) to offer clinical information systems to reduce the documentation process time of heart-lung machines, blood/gas monitors, and heater-cooler units.
According to the new market research report eHealth Market is expected to reach USD 132.35 Billion by 2023 from USD 47.60 Billion in 2018, at a CAGR of 22.7%.Factors driving market growth include the regulatory mandates and government initiatives for the implementation of eHealth solutions; growing mHealth, telehealth, and remote patient monitoring markets; and increasing need to curtail the escalating healthcare costs.In addition, the emerging market in China, India, and Australia; rising shift towards patient-centric healthcare delivery; and growing use of eHealth solutions in outpatient care facilities are further increasing the demand for eHealth solutions and services.Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=11513143In 2017, the eHealth solutions segment accounted for the largest share of the eHealth market.The eHealth solutions segment will continue to dominate the eHealth market, mainly due to the high demand of eHealth solutions due to the benefit of improved patient safety and patient care, stringent regulations, increasing government initiatives supporting the growth of these solutions, and the need to improve the efficiency of healthcare services by reducing medical errors.Healthcare consumers are expected to register the highest CAGR during the forecast period.The growth in this end-user segment can be attributed to the factors such as the increasing number of people requiring remote patient monitoring, rising demand for personalized care, and high penetration of digital technologies in the healthcare industry.In 2017, North America dominated the global eHealth market.The large share of this regional segment can be attributed to the region’s favorable regulatory scenario, the high adoption of eHealth solutions to curtail soaring healthcare costs, regulatory requirements regarding patient safety, and the presence of a large number of healthcare IT companies.Get Sample Pages: https://www.marketsandmarkets.com/requestsample.asp?id=11513143Research MethodologyTop-down and bottom-up approaches were used to validate the size of the global eHealth market and estimate the size of various other dependent submarkets.Major players in the market were identified through secondary sources secondary sources; directories; databases such as Hoovers, Bloomberg Businessweek, Factiva, and OneSource, journals and associations such as American Health Information Management Association, Ohio Health Information Management Association and their market revenues were determined through primary and secondary research.
According to the new market research report Defibrillators Market is projected to reach USD 10,883.3 million by 2022 from USD 9,323.5 million in 2017 at a CAGR of 3.1%. Factors such as technological advancements in defibrillators, increasing burden of target diseases, growing focus on providing public-access defibrillators, and rising number of training & awareness programs on defibrillators are driving the growth of this market.Read More: https://www.marketsandmarkets.com/PressReleases/automated-external-defibrillator.asp The report analyzes the global market by product, end user, and region.The implantable cardioverter defibrillators (ICDs) segment is expected to account for the largest share of the defibrillators market, by product type, in 2017On the basis of products, the market is classified into implantable cardioverter defibrillators (ICDs) and external defibrillators. The ICDs product segment is bifurcated into transvenous implantable cardioverter defibrillators (T-ICDs) and subcutaneous implantable cardioverter defibrillators (S-ICDs). The T-ICDs segment is further classified into single-chamber ICDs, dual-chamber ICDs, and cardiac resynchronization therapy defibrillators (CRT-Ds). The external defibrillators segment is further classified into manual external defibrillators, automated external defibrillators (AEDs), and wearable cardioverter defibrillators (WCDs).This report covers the defibrillators market data across four major geographies, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the global market in 2017, followed by Europe. The large share in the North American region is mainly attributed to the rising incidence of target diseases in the region, technological advancements in defibrillators, and increasing number of public defibrillation programs in the region. Factors such as the rapidly growing aging population, increasing cases of cardiovascular diseases, improving research infrastructure, and growing focus of key market players to expand their presence in this region are driving the growth of the Asia Pacific market.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=549 North America dominated the global defibrillators market in 2017The large share of the North American market can mainly be attributed to the continuous technological advancements and product innovations, increasing number of public defibrillation programs, and rising focus of key players to expand their business in the North American region.ZOLL Medical (US) held the leadership position in the global external defibrillators market. The company adopted new product launches, agreements, and partnerships as its core business strategies to enhance its share in the global external market. Other prominent players in the global external market included Philips (Netherlands), Physio-Control (US), Cardiac Science (US), Nihon Kohden (Japan), SCHILLER (Switzerland), Mindray Medical (China), Mediana (South Korea), METRAX (Germany), and METsis (Turkey).Contact:Mr. Shelly SinghMarketsandMarkets™ INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: [email protected]
According to the new market research report Spinal Implants Market is expected to reach USD 17.27 billion by 2021, growing at CAGR of 5.3% during the forecast period.Technological advancements in spine surgery devices, and increasing aging and obese population with increasing number of spine deformities, and rising demand for minimally invasive spine surgery procedures are the key factors fuelling the growth of the spinal surgery devices market.Read More: https://www.marketsandmarkets.com/PressReleases/spine-surgery-devices.asp Motion preservation/non-fusion technology segment to grow at fastest rate during the forecast period.On the basis of technology, the global spinal implants market is segmented into three categories, namely, spinal fusion and fixation, vertebral compression fracture treatment, spinal decompression, and motion preservation/non-fusion technologies.The motion preservation/non-fusion segment is expected to grow at the highest CAGR in the next five years, owing to the development of technologically advanced non-fusion devices and rising demand for minimally invasive surgical procedures among patients.The spinal fusion and fixation technology segment has been further divided into two categories, namely, fusion and fixation.The motion preservation/non-fusion technologies segment is further categorized into dynamic stabilization, artificial disc replacement, annulus repair, and disc nucleus replacement.Based on the type of product, the spinal implants market is classified into seven segments, namely, thoracic fusion and lumbar fusion devices, cervical fusion devices, spine biologics, vertebral compression fracture treatment devices, non-fusion treatment devices, spinal decompression devices, and spine bone stimulators.
According to research report the global cancer biomarkers market is projected to reach USD 20.48 billion by 2022 from USD 11.53 billion in 2017, at a CAGR of 12.2%.Cancer biomarkers are substances or processes that are indicative of the presence of cancers in the human body.Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer.They can be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids.They enhance cancer detection and facilitate high-speed noninvasive diagnosis using genomics and proteomics.Read More: https://www.marketsandmarkets.com/PressReleases/oncology-biomarkers-market.asp Based on cancer type, the breast cancer segment accounted for the largest share of the market in 2016The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin’s lymphoma, kidney, and other cancers, such as cervical, multiple myeloma, and CNS, gastric, liver, pancreatic, oral cavity and pharynx, stomach, and ovarian cancers.Next generation sequencing (NGS)Sequencing is the process of determining the precise order of nucleotides in a DNA/RNA sample.The advent of rapid sequencing methods has greatly enhanced biological and medical research and the discovery of biomarkers.
More

Top